Takeda Pharmaceutical Company Limited
TAKWI
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.14% | 1.39% | 1.81% | 1.87% | 1.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.14% | 1.39% | 1.81% | 1.87% | 1.10% |
| Cost of Revenue | 1.04% | 4.56% | 4.24% | 9.65% | 10.12% |
| Gross Profit | -3.78% | -0.24% | 0.59% | -1.83% | -3.00% |
| SG&A Expenses | -0.89% | 1.04% | -0.55% | -0.87% | -1.00% |
| Depreciation & Amortization | 58.06% | -12.39% | -12.76% | -12.35% | -62.71% |
| Other Operating Expenses | 391.38% | -70.58% | 84.79% | -64.97% | -128.28% |
| Total Operating Expenses | 6.88% | -1.49% | -0.55% | -1.46% | -12.10% |
| Operating Income | -38.39% | 23.60% | 19.70% | 27.27% | 155.53% |
| Income Before Tax | -60.38% | 328.54% | 177.19% | 39.74% | 23.08% |
| Income Tax Expenses | 389.12% | 153.11% | 172.80% | 194.75% | -465.40% |
| Earnings from Continuing Operations | -86.47% | -1.61% | -30.01% | 7.55% | 37.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.35% | -17.00% | -58.04% | -60.63% | -70.50% |
| Net Income | -86.54% | -1.63% | -30.09% | 7.52% | 37.67% |
| EBIT | -38.39% | 23.60% | 19.70% | 27.27% | 155.53% |
| EBITDA | -23.00% | 9.76% | 7.62% | 11.91% | 54.84% |
| EPS Basic | -86.16% | -1.48% | -30.61% | 6.34% | 35.82% |
| Normalized Basic EPS | -45.41% | 31.19% | 29.58% | 57.78% | 345.39% |
| EPS Diluted | -86.70% | -3.07% | -32.06% | 5.32% | 35.82% |
| Normalized Diluted EPS | -45.35% | 30.35% | 28.53% | 56.70% | 348.14% |
| Average Basic Shares Outstanding | 0.32% | 0.69% | 0.99% | 1.00% | 0.97% |
| Average Diluted Shares Outstanding | -0.06% | 1.17% | 1.57% | 1.58% | 1.29% |
| Dividend Per Share | 2.22% | 1.44% | 1.44% | -2.89% | -2.89% |
| Payout Ratio | 6.95% | 0.09% | 0.40% | -0.10% | -0.30% |